Literature DB >> 10535333

Induction of CD40 on human endothelial cells by Alzheimer's beta-amyloid peptides.

J Tan1, T Town, Z Suo, Y Wu, S Song, A Kundtz, J Kroeger, J Humphrey, F Crawford, M Mullan.   

Abstract

Growing evidence suggests that beta-amyloid (Abeta) peptides play a central role in mediating vascular endothelium dysfunction, but the extent to which immune mechanisms are involved in this process remains unclear. To explore such mechanisms, we incubated cultured human aortic endothelial cells (HAEC) with freshly solublized Abeta and examined expression of a central immunoregulatory molecule, CD40, in these cells using reverse transcriptase-polymerase chain reaction, Western immunoblotting, and Flow cytometry. Our results show that treatment of endothelial cells with Abeta1-40, Abeta1-42 or gamma interferon (IFN-gamma) results in a dose-dependent induction of endothelial CD40 expression. Furthermore, ligation of endothelial CD40 and simultaneous treatment of human endothelial cells with IFN-gamma or Abeta peptides leads to a significant release of interleukin-1beta (IL-1beta), a marker for endothelial cell activation. Since IL-1beta is an important inflammatory response mediator, these findings suggest that the functional role of Abeta-induced endothelial CD40 may be promotion of the inflammatory cascade in vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10535333     DOI: 10.1016/s0361-9230(99)00122-7

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  14 in total

Review 1.  T-cells in Alzheimer's disease.

Authors:  Terrence Town; Jun Tan; Richard A Flavell; Mike Mullan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

2.  Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice.

Authors:  William V Nikolic; Huayan Hou; Terrence Town; Yuyan Zhu; Brian Giunta; Cyndy D Sanberg; Jin Zeng; Deyan Luo; Jared Ehrhart; Takashi Mori; Paul R Sanberg; Jun Tan
Journal:  Stem Cells Dev       Date:  2008-06       Impact factor: 3.272

Review 3.  Impact of the CD40-CD40L dyad in Alzheimer's disease.

Authors:  Brian Giunta; Kavon Rezai-Zadeh; Jun Tan
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

4.  Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand.

Authors:  Eileen M Higham; K Dane Wittrup; Jianzhu Chen
Journal:  J Immunol       Date:  2010-03-03       Impact factor: 5.422

5.  Role of CD40 in prion disease and the immune response to recombinant PrP.

Authors:  Richard Rubenstein; Allen Chiu; Binggong Chang; Thomas Wisniewski
Journal:  J Neuroimmunol       Date:  2013-02-16       Impact factor: 3.478

6.  Role of Aβ-receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase A₂ activation in astrocytes and cerebral endothelial cells.

Authors:  S Askarova; X Yang; W Sheng; G Y Sun; J C-M Lee
Journal:  Neuroscience       Date:  2011-09-28       Impact factor: 3.590

7.  Exploring autophagy-related prognostic genes of Alzheimer's disease based on pathway crosstalk analysis.

Authors:  Fang Qian; Wei Kong; Shuaiqun Wang
Journal:  Bosn J Basic Med Sci       Date:  2022-09-16       Impact factor: 3.759

8.  SOLUBLE CD40 LIGAND IN DEMENTIA.

Authors:  B Giunta; K P Figueroa; T Town; J Tan
Journal:  Drugs Future       Date:  2009-04-01       Impact factor: 0.148

Review 9.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

10.  Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD).

Authors:  Jon Salemi; Demian F Obregon; Anthony Cobb; Spenser Reed; Edin Sadic; Jingji Jin; Francisco Fernandez; Jun Tan; Brian Giunta
Journal:  Mol Neurodegener       Date:  2011-01-11       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.